Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Oriol

Showing results (211-220 of 250) with videos related to

Pageof 25
Sort By:
Lancet (London, England)|January 19, 2016
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trialSagar Lonial, Brendan M Weiss, Saad Z Usmani, et al.
Blood|April 28, 2016
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patientsBruno Paiva, Maria-Teresa Cedena, Noemi Puig, et al.
Haematologica|September 22, 2018
Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUXMeletios A Dimopoulos, Jesus San-Miguel, Andrew Belch, et al.
Hemasphere|June 22, 2026
Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencingNatalia Buenache, Marta Lasa, Andrés Arroyo, et al.
Blood|May 22, 2025
Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichmentMarta Lasa, Carmen Gonzalez, Laura Notarfranchi, et al.
The Lancet. Haematology|March 16, 2025
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 studyAjai Chari, Cyrille Touzeau, Carolina Schinke, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 10, 2022
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple MyelomaLuis-Esteban Tamariz-Amador, Paula Rodríguez-Otero, Ana Jiménez-Ubieto, et al.
The Lancet. Oncology|August 27, 2010
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trialMaría-Victoria Mateos, Albert Oriol, Joaquín Martínez-López, et al.
The Lancet. Haematology|August 6, 2025
Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trialMaría-Victoria Mateos, Bruno Paiva, M Teresa Cedena, et al.
The New England Journal of Medicine|December 9, 2024
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple MyelomaMeletios A Dimopoulos, Peter M Voorhees, Fredrik Schjesvold, et al.
Pageof 25

Showing results (211-220 of 250) with videos related to

Sort By:
Pageof 25
Lancet (London, England)|January 19, 2016
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trialSagar Lonial, Brendan M Weiss, Saad Z Usmani, et al.
Blood|April 28, 2016
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patientsBruno Paiva, Maria-Teresa Cedena, Noemi Puig, et al.
Haematologica|September 22, 2018
Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUXMeletios A Dimopoulos, Jesus San-Miguel, Andrew Belch, et al.
Hemasphere|June 22, 2026
Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencingNatalia Buenache, Marta Lasa, Andrés Arroyo, et al.
Blood|May 22, 2025
Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichmentMarta Lasa, Carmen Gonzalez, Laura Notarfranchi, et al.
The Lancet. Haematology|March 16, 2025
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 studyAjai Chari, Cyrille Touzeau, Carolina Schinke, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 10, 2022
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple MyelomaLuis-Esteban Tamariz-Amador, Paula Rodríguez-Otero, Ana Jiménez-Ubieto, et al.
The Lancet. Oncology|August 27, 2010
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trialMaría-Victoria Mateos, Albert Oriol, Joaquín Martínez-López, et al.
The Lancet. Haematology|August 6, 2025
Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trialMaría-Victoria Mateos, Bruno Paiva, M Teresa Cedena, et al.
The New England Journal of Medicine|December 9, 2024
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple MyelomaMeletios A Dimopoulos, Peter M Voorhees, Fredrik Schjesvold, et al.
Pageof 25